| Denosumab (n = 48) | Zoledronic acid (n = 56) |
Median age (years) | 65.3 (51~79) | 63.1 (55~78) |
Pathological method |
|
|
Radical prostatectomy | 10 | 13 |
Prostatic puncture | 36 | 41 |
Bone puncture | 2 | 2 |
Gleason score |
|
|
6 | 4 | 6 |
7 | 8 | 10 |
8 | 8 | 10 |
9 | 14 | 14 |
10 | 14 | 16 |
Bone metastasis at first Diagnosis | 30 | 36 |
Hormone resistance | 18 | 21 |
Site of bone metastasis |
|
|
Quadrilateral bone | 12 | 13 |
Spine | 16 | 19 |
Multiple bone metastases | 20 | 24 |
Abnormal renal function | 5 | 6 |
Spinal cord compression | 5 | 5 |
Concomitant therapy |
|
|
Endocrine therapy | 42 | 50 |
Chemotherapy | 10 | 12 |
Bone operation | 3 | 2 |
Radiotherapy |
|
|
Bone metastasis | 15 | 17 |
Prostate | 18 | 23 |
PSA (ug/L) | 18 (6.7~55) | 16 (7~49) |
Basal bone pain (NRS score) |
|
|
≤3 | 33 | 39 |
4~6 | 10 | 7 |
7~10 | 5 | 7 |
Median duration of medication (month) | 12 (8~24) | 13 (10~27) |